Filter Options
Required*
Filter
Cambridge / Massachusetts / United States
0.0
Cambridge / Massachusetts / United States
0.0
Cambridge / Massachusetts / United States
0.0
ARIAD Pharmaceuticals, based in Cambridge, Mass., is developing new medicines that regulate cell-signaling pathways implicated in cancer. Its pipeline includes a series of small molecule product candidates that provide targeted and potent anti-cancer activity to treat solid tumors and hematologic cancers, as well as the spread of tumors to distant sites. Its lead candidate, AP23573, a novel mTOR inhibitor, has been given fast-track designation by the Food and Drug Administration, and is in Phase 2 of development. It is for the treatment of soft-tissue and bone sarcomas. ARIAD Pharmaceuticals other products at the preclinical stage of development, and are oncogenic kinase inhibitors, bone-targeted mTOR inhibitors, and AP 23573 stents.
Cambridge / Massachusetts / United States
0.0
Hydra Biosciences is a privately held biopharmaceutical company. It has a staff of trained and certified professionals, including advisors, investors, executive officers and financers. The company conducts drug discovery programs that focuses on channels implicated in pain and inflammation diseases. Hydra Biosciences offers medicines for cell-based therapies for organ and tissue restoration. The company s group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec and Boston Medical Investors. It also focuses on therapeutic areas, such as cardiovascular and pulmonary diseases. Hydra Biosciences is located in Cambridge, Mass.
Cambridge / Massachusetts / United States
0.0